Effect of pirfenidone on breathlessness in patients with idiopathic pulmonary fibrosis

New post hoc analysis of IPF clinical trials suggests that treatment with pirfenidone slows the worsening of patient-reported breathlessness over 12 months versus placebo in patients with more advanced disease (GAP stage II/III or FVC <80%) http://bit.ly/2yJyUVT

Detalles Bibliográficos
Autores principales: Glassberg, Marilyn K., Wijsenbeek, Marlies S., Gilberg, Frank, Petzinger, Ute, Kirchgaessler, Klaus-Uwe, Albera, Carlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2019
Materias:
Agora
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6766683/
https://www.ncbi.nlm.nih.gov/pubmed/31164431
http://dx.doi.org/10.1183/13993003.00399-2019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6766683/
https://www.ncbi.nlm.nih.gov/pubmed/31164431
http://dx.doi.org/10.1183/13993003.00399-2019

Ejemplares similares